Topics

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation

2018-07-09 09:20:14 | BioPortfolio

Summary

To evaluate the efficacy on abdominal symptoms (abdominal bloating, abdominal discomfort, and abdominal pain) and safety of linaclotide 290 μg administered orally to patients with irritable bowel syndrome with constipation (IBS-C).

Description

12 week treatment period followed by 4-week Randomized Withdrawal (RW) Period.

Study Design

Conditions

Irritable Bowel Syndrome Characterized by Constipation

Intervention

Linaclotide, Placebo

Location

Clinical Research Associates
Huntsville
Alabama
United States
35801

Status

Recruiting

Source

Ironwood Pharmaceuticals, Inc.

Results (where available)

View Results

Links

Published on BioPortfolio: 2018-07-09T09:20:14-0400

Clinical Trials [2852 Associated Clinical Trials listed on BioPortfolio]

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

The purpose of this study is to determine the safety and efficacy of linaclotide administered to patients with Irritable Bowel Syndrome with Constipation (IBS-C).

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with irritable bowel syndrome with constipation (IBS-C). The primary efficacy p...

An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

The primary objective of this study is to assess the potential of linaclotide treatment to induce the development of anti-drug antibodies (ADAs). The secondary objectives are to provide ad...

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

The objectives of this study are to evaluate the safety, efficacy, and dose response of two delayed release formulations of linaclotide (DR; DR formulation 1 is DR1; DR formulation 2 is DR...

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of Irritable Bowel syndrome with Constipation (IBS-C), in children age 7-17 years. This s...

PubMed Articles [10755 Associated PubMed Articles listed on BioPortfolio]

The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications: Real-World Evidence From the CONTOR Study.

This study aimed to characterize the impact of stool consistency on patient-reported bowel movement (BM) satisfaction in patients with irritable bowel syndrome with constipation (IBS-C) or chronic idi...

Future Possibility of Mizagliflozin on Functional Constipation and/or Irritable Bowel Syndrome with Constipation.

Tegaserod for the Treatment of Irritable Bowel Syndrome.

Tegaserod (Zelnorm®) is a 5-hydroxytryptamine (serotonin) type 4 receptor agonist for the treatment of hypomotility disorders of the lower gastrointestinal tract associated with the irritable bowel s...

Stress and a sedentary lifestyle are associated with irritable bowel syndrome in medical students from Peru: a cross-sectional study.

Previous studies suggest that medical students may have higher rates of irritable bowel syndrome as compared to the general population. We hypothesized lifestyle characteristics may be associated to i...

EVALUATION OF CARBOHYDRATE AND FIBER CONSUMPTION IN PATIENTS WITH IRRITABLE BOWEL SYNDROME IN OUTPATIENT TREATMENT.

Irritable bowel syndrome (IBS) is a chronic functional condition, which main symptoms of pain, discomfort and abdominal distension, constipation, diarrhea, altered fecal consistency and sensation of i...

Medical and Biotech [MESH] Definitions

A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.

Chronic or recurrent colonic disorders without an identifiable structural or biochemical explanation. The widely recognized IRRITABLE BOWEL SYNDROME falls into this category.

A subspecies of Bifidobacterium longum that occurs in the GASTROINTESTINAL TRACT of human infants and is used as a PROBIOTIC. It may also be used in the treatment of IRRITABLE BOWEL SYNDROME.

A diphenylmethane stimulant laxative used for the treatment of constipation and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)

A malabsorption syndrome resulting from extensive operative resection of the SMALL INTESTINE, the absorptive region of the GASTROINTESTINAL TRACT.

More From BioPortfolio on "A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation"

Quick Search

Relevant Topics

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...

Irritable Bowel Syndrome IBS
Irritable bowel syndrome (IBS) is a common but poorly understood chronic (long-term) condition where the normal functions of the bowel are disrupted. Symptoms of IBS include abdominal pain or discomfort, changes in bowel habits and bloated feelings. ...


Searches Linking to this Trial